Key result
A review of antiplatelet therapy in children highlights the lack of large interventional trials, leading to uncertainty in therapeutic indications, recommended doses, and side effects.
This review summarizes the therapeutic indications, recommended doses, contraindications, and side effects of antiplatelet agents in children, highlighting the lack of large interventional trials in this population compared to adults.
Pediatric antiplatelet use should remain cautious and individualized; leaves open the need for large dedicated RCTs.
Antiplatelet agents are administered in the treatment of a large number of adult diseases: coronary heart disease, ischemic stroke, peripheral arterial disease, arrhythmias with their thromboembolic complications, primary and secondary prevention. In childhood however, the situation is substantially different. The lack of large interventional trials on the use of antiplatelet drugs in children, has led to greater uncertainty, and a less extensive use of these drugs, limited to fewer indications. The purpose of this article was to review the studies conducted to date on the use of antiplatelet agents in children. A concerted effort has been made to identify which are the shared therapeutic indications of this class of compounds, the recommended dose, the contraindications and the possible side effects. In brief, an attempt has been made to ascertain the interesting potential of these drugs which are so often neglected in children.
No takes yet. Share an insight, caveat, or question.
Bassareo et al. (2012) conducted a review in Pediatric diseases requiring antiplatelet therapy. Antiplatelet agents was evaluated. A review of antiplatelet therapy in children highlights the lack of large interventional trials, leading to uncertainty in therapeutic indications, recommended doses, and side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: